At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 41 enrolled
Drug / intervention
AIN457 +1 moredrug
Likely dose
AIN457 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Double-blind, Placebo Controlled, Multicenter, Bridging Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Sixteen Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy Follow-up to One Year in Chinese Subjects With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating AIN457 and Secukinumab Placebo for Psoriatic Arthritis. Completed, enrolled 41 participants across 12 sites.
Detailed Summary
The purpose of this study was to assess the efficacy and safety of secukinumab in Chinese participants with active Psoriatic arthritis (PsA ) compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJun 2021
Primary CompletionJun 2022
Study CompletionMar 2023
TodayJul 2026
First PostedJan 15, 2021
Enrollment StartJun 24, 2021
Primary CompletionJun 2, 2022
Study CompletionMar 10, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.5 years ago
Interventions
AIN457drug
Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Secukinumab Placeboother
Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection